



**Name** : Dr. Rahul G. Ingle  
**Designation** : Professor  
**Qualification** : M. Pharm., Ph.D., Post-doc  
**Specialization** : Pharmaceutical Chemistry  
**E mail id** : [rahul.pharmacy@dmihher.edu.in](mailto:rahul.pharmacy@dmihher.edu.in)  
**Phone** : +91-99-23169327  
**Experience** : 12 Years

At present working as a Professor at Datta Meghe College of Pharmacy, DMIMS (DU), Wardha. He has 03 years of academic experience and 06 years of research experience at Rose-labs Bioscience, Ahmedabad and Wockhardt Research Centre, Aurangabad (India). In addition, 03 years of post-doctoral experience from the World class Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang University, Hangzhou, China.

**Research areas:**

- Synthetic Chemistry
- Drug Design
- Analytical Chemistry
- Biopharmaceuticals

**Research Contributions**

- Research Publications: 39 (International: 35, National-04)
- Books: 03
- Patents: 01 Published
- Paper Presentations: 06 (International: 05, National: 01)
- Industrial Experience
  - Sound experience in **RNA synthesis** with **biopharmaceutical formulations (monoclonal antibodies, fused proteins, and nucleic acids)** stability study and their analysis.
  - Executed industry-based biopharmaceutical projects on **various monoclonal antibodies** in collaboration with **Institute of Innovative Medicine, Hangzhou Biopharma Town, China.**

- Performed **forced degradation** studies on **monoclonal antibodies** and their analysis.

- Performed stability studies on various NCE's as per **ICH guidelines**.
- Screening of quinoxaline derivatives for **in-vivo anticancer** activity on human 60-cell lines from the **National Cancer Institute; USA**.
- During my industrial carrier; I had worked on enoxaparin (LMWHs), along with billion-dollar **anti-infective NCE** projects i.e., Nafithromycin, Zidebactam, Levonadifloxacin, ESBL, WCK-771, WCK-5222, WCK-4282, WCK-2349, Tazobactam, etc., which received **QIDP** approval from **US-FDA**. In 2020 **DCGI, India** has approved Emrok (Levonadifloxacin).
- Sound experience at the **New Drug Discovery (R&D) Department of Wockhardt Research Centre** in drug analysis and testing.
- Handling skills on sophisticated analytical instruments e.g., NMR-400, GC-MS, LC-MS, CHN analyzer, GC, HPLC, MFI, DLS, EPR, FTIR, UV, Polarimeter, Coulometer, KF-Titrator, pH meter, Refractometer, etc.
- During my doctorate, I have synthesized quinoxaline derivatives and collaboratively worked with **Tropical Disease Research Centre; MGIMS; Medical College; Sewagram; Wardha** for the **Infectious Filariasis** screening.
- **Conferences/Workshops/Seminars attended- 14**
- **Professional Recognition/ Award/ Prize/ Certificate, Fellowships**
- Intellectual Property Rights (IPR), WIPO Geneva, Switzerland.
- Received —Research Fellowship| from All India Council for Technical Education(AICTE), New Delhi, India.
- Qualified GATE – Pharmacy 2009, 95 %
- Certificate of Merit, GCOP, Aurangabad.
- Best Cricketer Award, GCOP, Aurangabad.
- Blood Donation Camp Organizer Award, Civil Hospital, Amravati.

## Recent Publications

- Jia-Yi Lv, **Rahul G. Ingle**, Wei-Jie Fang, Histidine as a versatile excipient in the protein-based biopharmaceutical formulations (**International Journal of Pharmaceutics- Impact factor: 5.3**)
- Satish Rojekar, **Rahul G. Ingle**, Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery (**Pharmaceutics- Impact factor: 4.9**)
- Meng-Jia Jin, Jia-Wei Liu<sup>1</sup>, **Rahul G. Ingle**, Wei-Jie Fang, The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking (**Pharmaceutical Research- Impact factor: 3.7**)
- Shivani Makhijani, Gehan M. Elossaily, Satish Rojekar & **Rahul G. Ingle**, mRNA-based vaccines – global approach, challenges, and could be a promising wayout for future pandemics (**Pharmaceutical Development and Technology, Impact factor: 3.75**)
- RD Jawarkar, MEA Zaki, **RG Ingle**, Application of In-silico Drug Discovery

Techniques to Discover a Novel Hit for Target-Specific Inhibition of SARS-CoV-2 Mpro's Revealed Allosteric binding with MAO-B receptor: A theoretical study to Find a cure for post Covid Neurological disorder (**PLOS One- Impact factor: 3.75**)

- **RG Ingle**, WJ Fang, An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics (**Pharmaceutics- Impact factor: 6.57**)
- **RG Ingle**, Su Zheng, H, Jiang, WJ Fang, Current development of bioanalytical sample preparation techniques in pharmaceuticals (**Journal of Pharmaceutical Analysis- Impact factor: 14.03**)
- WJ Fang, **RG Ingle**, JW Liu, XZ Ge, H Wang, Freeze-dried monoclonal antibody formulations are unexpectedly more prone to degradation than liquid formulations under shaking stress (**Journal of Pharmaceutical Sciences- Impact factor: 3.78**)
- **RG Ingle**, WJ Fang, Pre-filled dual-chamber devices (DCDs) – Promising high-quality and convenient drug delivery system (**International Journal of Pharmaceutics- Impact factor: 6.51**)
- C. Qian, G. Wang, **RG Ingle**, WJ Fang, Formation of protein sub-visible particles during powder grinding of a monoclonal antibody (**European Journal of Pharmaceutics and Biopharmaceutics- Impact factor: 5.59**)
- VP Rane, RA Jadhav, **RG Ingle**, RD Yeole, Enantiomeric separation and thermodynamic investigation of (R)-5-[1-(4-Nitrobenzylsulfonyloxy)-ethyl]-5-(pyridine-2-yl)-[1,3,4]-thiadiazole, a Key Intermediate of Nafithromycin (**Analytical Chemistry Letters- Impact factor: 1.0**)
- **RG Ingle**, PS Bhoj, R. Reddy, SJ Wadher, K. Goswami, Apoptotic impact on *Brugia malayi* by sulphonamido quinoxaline: search for a novel therapeutic rational ( **Parasitology Research - Impact factor: 2.57**)
- **RG Ingle**, AS Agrawal, World of low molecular weight heparins (LMWHs): Enoxaparin as a promising moiety—A review (**Carbohydrate Polymers- Impact factor: 10.72**)
- **RG Ingle**, AS Agrawal, Pre-filled syringe - a ready-to-use drug delivery system - a review (**Expert Opinion on Drug Delivery- Impact factor: 5.55**)
- **RG Ingle**, DD Magar, RP MArathe, HM Patel, Sulfonamido quinoxaline: Search for anticancer agents (**European Journal of Medicinal Chemistry- Impact factor: 7.09**)



